BRPI0411255A - compound, pharmaceutical composition, use of a compound, methods of treating a disorder of a patient, and process for the preparation of a compound - Google Patents
compound, pharmaceutical composition, use of a compound, methods of treating a disorder of a patient, and process for the preparation of a compoundInfo
- Publication number
- BRPI0411255A BRPI0411255A BRPI0411255-5A BRPI0411255A BRPI0411255A BR PI0411255 A BRPI0411255 A BR PI0411255A BR PI0411255 A BRPI0411255 A BR PI0411255A BR PI0411255 A BRPI0411255 A BR PI0411255A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- treating
- methods
- pharmaceutical composition
- disorder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, MéTODOS DE TRATAR UM DISTúRBIO DE UM PACIENTE, E, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO". Novos carbamatos de piridinila substituídos da fórmula geral (I): composições farmacêuticas que os compreende e o uso destes no tratamento e/ou prevenção de doenças e distúrbios relacionados a lipase sensível a hormónio. Mais particularmente, os compostos são úteis para o tratamento e/ou prevenção de doenças e distúrbios em que a modulação da atividade da lipase sensível a hormónio é benéfica."COMPOUND, PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND, METHODS OF TREATING A PATIENT DISORDER, AND PROCESS FOR PREPARING A COMPOUND". Novel substituted pyridinyl carbamates of general formula (I): pharmaceutical compositions comprising them and their use in the treatment and / or prevention of hormone sensitive lipase related diseases and disorders. More particularly, the compounds are useful for treating and / or preventing diseases and disorders where modulation of hormone sensitive lipase activity is beneficial.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200300879 | 2003-06-12 | ||
US47852603P | 2003-06-13 | 2003-06-13 | |
PCT/DK2004/000391 WO2004111031A1 (en) | 2003-06-12 | 2004-06-08 | Pyridinyl carbamates as hormone-sensitive lipase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0411255A true BRPI0411255A (en) | 2006-08-01 |
Family
ID=33553690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0411255-5A BRPI0411255A (en) | 2003-06-12 | 2004-06-08 | compound, pharmaceutical composition, use of a compound, methods of treating a disorder of a patient, and process for the preparation of a compound |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1636205A1 (en) |
JP (1) | JP2006527210A (en) |
KR (1) | KR20060017791A (en) |
AU (1) | AU2004247319A1 (en) |
BR (1) | BRPI0411255A (en) |
CA (1) | CA2526204A1 (en) |
MX (1) | MXPA05013224A (en) |
NO (1) | NO20060168L (en) |
RU (1) | RU2337908C2 (en) |
WO (1) | WO2004111031A1 (en) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050026844A1 (en) | 2003-04-03 | 2005-02-03 | Regents Of The University Of California | Inhibitors for the soluble epoxide hydrolase |
US20090018092A1 (en) | 2004-03-16 | 2009-01-15 | The Regents Of The University Of California | Reducing Nephropathy with Inhibitors of Soluble Epoxide Hydrolase and Epoxyeicosanoids |
WO2006045119A2 (en) | 2004-10-20 | 2006-04-27 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
JP2008530173A (en) * | 2005-02-15 | 2008-08-07 | ノボ ノルディスク アクティーゼルスカブ | Methylphenylcarbamic acid 5- (4-isobutyl-2,6-dioxopiperazin-1-yl) pyridin-2-yl esters and salts as hormone sensitive lipase inhibitors |
US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
EP1928847A4 (en) * | 2005-08-29 | 2011-08-10 | Gerard M Housey | Theramutein modulators |
TW200808723A (en) * | 2006-03-13 | 2008-02-16 | Univ California | Conformationally restricted urea inhibitors of soluble epoxide hydrolase |
AU2013205325B2 (en) * | 2006-03-27 | 2016-03-24 | The Regents Of The University Of California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
LT3412290T (en) | 2006-03-27 | 2021-04-26 | The Regents Of The University Of California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
AU2016201061B2 (en) * | 2006-03-27 | 2017-03-02 | The Regents Of The University Of California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
KR101456722B1 (en) * | 2006-03-29 | 2014-10-31 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Diarylthiohydantoin compounds |
MX2009002905A (en) * | 2006-09-21 | 2009-06-19 | Piramal Life Sciences Ltd | 3 -amino- pyridine derivatives for the treatment of metabolic disorders. |
FR2912404B1 (en) | 2007-02-09 | 2009-04-10 | Sanofi Aventis Sa | AZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE. |
JP5535925B2 (en) | 2007-10-26 | 2014-07-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Diarylhydantoin compounds as androgen receptor modulators |
ME01573B (en) | 2009-05-12 | 2014-09-20 | Addex Pharma Sa | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
EP2528604B1 (en) | 2010-01-29 | 2017-11-22 | The Regents of the University of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
EA028869B1 (en) | 2010-02-16 | 2018-01-31 | Арагон Фармасьютикалс, Инк. | Androgen receptor modulators and use thereof |
WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
CA3142817A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation |
AU2013323861C1 (en) | 2012-09-26 | 2024-05-02 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
JOP20200097A1 (en) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | Androgen receptor modulator and uses thereof |
SG11201507453VA (en) | 2013-03-15 | 2015-10-29 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
KR102293060B1 (en) | 2013-03-15 | 2021-08-23 | 글로벌 블러드 테라퓨틱스, 인크. | Compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
AU2014237340C1 (en) | 2013-03-15 | 2018-11-08 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
AU2014251442A1 (en) | 2013-04-12 | 2015-12-03 | Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises" | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
UA119247C2 (en) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Spirocyclic compounds as tryptophan hydroxylase inhibitors |
EA202092627A1 (en) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION |
WO2015089137A1 (en) | 2013-12-11 | 2015-06-18 | Karos Pharmaceuticals, Inc. | Acylguanidines as tryptophan hydroxylase inhibitors |
RS61653B1 (en) | 2014-02-07 | 2021-04-29 | Global Blood Therapeutics Inc | Crystalline polymorph of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
WO2016109501A1 (en) | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
US9611201B2 (en) | 2015-03-05 | 2017-04-04 | Karos Pharmaceuticals, Inc. | Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone |
MX2018006832A (en) | 2015-12-04 | 2018-11-09 | Global Blood Therapeutics Inc | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl) pyridin-3-yl)methoxy)benzaldehyde. |
TWI726969B (en) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | Substituted thiohydantoin derivatives as androgen receptor antagonists |
TWI752307B (en) | 2016-05-12 | 2022-01-11 | 美商全球血液治療公司 | Novel compound and method of preparing compound |
TW202332423A (en) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
EP3697398A1 (en) | 2017-10-16 | 2020-08-26 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
ES2966707T3 (en) | 2018-10-01 | 2024-04-23 | Global Blood Therapeutics Inc | Hemoglobin modulators for the treatment of sickle cell disease |
US11203597B2 (en) | 2018-11-14 | 2021-12-21 | Altavant Sciences Gmbh | Crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing |
US10683285B2 (en) | 2018-11-19 | 2020-06-16 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10010968A1 (en) * | 2000-03-07 | 2001-09-13 | Aventis Pharma Gmbh | New 5-alkoxy-3-phenyl-3H-1,3,4-oxadiazol-2-one derivatives, are hormone-sensitive lipase inhibitors useful for treating metabolic disorders such as non-insulin dependent diabetes mellitus |
WO2001087843A1 (en) * | 2000-05-15 | 2001-11-22 | Novo Nordisk A/S | Compounds for treating disorders where a decreased level of plasma ffa is desired |
JP2005518376A (en) * | 2001-12-14 | 2005-06-23 | ノボ ノルディスク アクティーゼルスカブ | Compounds and their use to reduce the activity of hormone sensitive lipases |
-
2004
- 2004-06-08 RU RU2005137716/04A patent/RU2337908C2/en not_active IP Right Cessation
- 2004-06-08 MX MXPA05013224A patent/MXPA05013224A/en not_active Application Discontinuation
- 2004-06-08 CA CA002526204A patent/CA2526204A1/en not_active Abandoned
- 2004-06-08 KR KR1020057021923A patent/KR20060017791A/en not_active Application Discontinuation
- 2004-06-08 BR BRPI0411255-5A patent/BRPI0411255A/en not_active IP Right Cessation
- 2004-06-08 WO PCT/DK2004/000391 patent/WO2004111031A1/en active Application Filing
- 2004-06-08 AU AU2004247319A patent/AU2004247319A1/en not_active Abandoned
- 2004-06-08 JP JP2006515703A patent/JP2006527210A/en not_active Withdrawn
- 2004-06-08 EP EP04736303A patent/EP1636205A1/en not_active Withdrawn
-
2006
- 2006-01-12 NO NO20060168A patent/NO20060168L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2006527210A (en) | 2006-11-30 |
RU2337908C2 (en) | 2008-11-10 |
AU2004247319A1 (en) | 2004-12-23 |
MXPA05013224A (en) | 2006-03-09 |
KR20060017791A (en) | 2006-02-27 |
EP1636205A1 (en) | 2006-03-22 |
WO2004111031A1 (en) | 2004-12-23 |
NO20060168L (en) | 2006-03-10 |
CA2526204A1 (en) | 2004-12-23 |
RU2005137716A (en) | 2006-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0411255A (en) | compound, pharmaceutical composition, use of a compound, methods of treating a disorder of a patient, and process for the preparation of a compound | |
BR0012136A (en) | Highly selective norepinephrine reabsorption inhibitors and methods of using them | |
BR0214967A (en) | Compound, pharmaceutically acceptable salt, process for preparing a compound, pharmaceutical composition, use of a compound and method of treating a patient disorder | |
BR9810592A (en) | Compound, processes for preparing a compound, for treating or preventing diseases of the endocrine system and for the manufacture of a drug, pharmaceutical composition, and, use of a compound | |
BR9808953A (en) | Compound, process to treat a cyclooxygenase-2 mediated disorder in a patient, and pharmaceutical composition | |
BR0307351A (en) | Compound, pharmaceutical composition, method for treating a p38 kinase activity-mediated or cytokine-mediated condition or condition produced by p38 kinase activity, use of a compound, and process for preparing a compound | |
BR0312464A (en) | Tyrosine kinase inhibitors | |
BR0211119A (en) | Compound, method of treating a patient who has, or preventing a patient from catching, a disease or condition, use of a compound, and method for making a compound | |
BR0313266A (en) | Compounds, their preparation and use processes, pharmaceutical formulation and methods for preventing and / or treating a mglur5 receptor mediated disorder and inhibiting mglur5 receptor activation | |
BRPI0512253A (en) | compound, pharmaceutical formulation, use of a compound, method of treating a disease, combined product, and process for preparing a compound | |
BR0213540A (en) | Compounds, method for treating a patient's illness or disorder and a pharmaceutical composition comprising them | |
BR9813373A (en) | Compound, process for preparing it, pharmaceutical composition, process for preparing it, use of a compound, and, processes for effecting immunosuppression and for treating or reducing the risk of reversibly obstructive airway disease in a patient | |
BR9911482A (en) | Compound, pharmaceutical composition, use of the compound, and, processes for the treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound | |
BR0116370A (en) | Compound, pharmaceutical composition, use of a compound, and method of treating an hppar-mediated disease or condition in a patient. | |
BR0214988A (en) | S-enanciomer of a compound, compound, pharmaceutical formulation, method of treating or preventing lipid disorders, use of a compound, method of treating or preventing type 2 diabetes, process for preparing a compound, and, pharmaceutical composition | |
BRPI0512252A (en) | compound or a pharmaceutically acceptable salt thereof, pharmaceutical formulation, use of a compound, method of treating a disease, combined product, and process for preparing a compound | |
ATE361084T1 (en) | TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING PROANTHOCYANIDINS, GLYCYRRHETINIC ACID AND TELMESTEINS FOR THE TREATMENT OF DERMATITIS | |
UY26130A1 (en) | COMPOUNDS TO TREAT OBESITY | |
ATE442142T1 (en) | FREDERICAMYCIN DERIVATIVES AS DRUGS FOR TUMOR TREATMENT | |
BR0307291A (en) | Compound; process for the preparation of a compound; pharmaceutical composition; use of a compound; method for the treatment and prophylaxis of various disorders and obesity in a human | |
BRPI0417376A (en) | compounds, process for the manufacture thereof, pharmaceutical compositions comprising them, method for treating and / or prophylaxis of diseases that are associated with cb1 receptor modulation and their use | |
BRPI0418099A (en) | compounds, pharmaceutical composition, and use of a compound | |
BRPI0410316A (en) | compound, pharmaceutical composition, use of the compounds, and method of treating vr1-mediated disorders and for the treatment of pain disorders | |
BR0211118A (en) | Compound, methods for treating or preventing disease and for making a compound, intermediate, and use of a compound or salt | |
BR0212787A (en) | Pharmaceutically acceptable compound or salt thereof, methods of treating or preventing disease and preparing a compound, use of a compound or salt, and pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |